en · de · es · fr · pt
creatine-notes.peptides6908.com › Faq › Albumin Binding And Duration Of Action — Deep Dive

Albumin Binding And Duration Of Action — Deep Dive

By Editorial Desk · published 2026-06-20 · last reviewed 2026-08-01 · Faq

The short version of DAC fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Albumin Binding and Duration of Action

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Cjc-1295 at a glance

PropertyValueNotes
Duration with linkerSeveral daysReported in early human work
Duration without linkerTens of minutesShort plasma residence
Albumin attachment siteCysteine-34Covalent maleimide reaction
Primary receptorPituitary GHRH receptorStimulates growth hormone release
Downstream markerInsulin-like growth factor 1Indirect measure of activity

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Related pages on this site

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Background and Molecular Design

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.

Analytical Characterization and Storage

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Supporting material

== Metabolism == Levamisole is readily absorbed from the gastrointestinal tract and metabolized in the liver. Its time to peak plasma concentration is 1.5–2 hours. The plasma elimination half-life is fairly quick at 3–4 hours which can contribute to not detecting levamisole intoxication. The metabolite half-life is 16 hours. Levamisole's excretion is primarily through the kidneys, with about 70% being excreted over 3 days. Only about 5% is excreted as unchanged levamisole. Drug testing of racehorse urine has led to the revelation that among levamisole equine metabolites are both pemoline and aminorex, stimulants that are forbidden by racing authorities. Further testing confirmed aminorex in human and canine urine, meaning that both humans and dogs also metabolize levamisole into aminorex, though it is unclear whether plasma aminorex is present at any appreciable level. Blood samples following oral administration of levamisole out to 172 hr post-dose did not demonstrate any plasma aminorex levels above that of the limit of quantification (LoQ). Additionally, in cocaine-positive plasma samples, of which 42% contained levamisole, aminorex was never reported at concentrations higher than LoQ.

Adenosine production and lack of ammonia overproduction seem to strongly suppress rhabdomyolysis down to the purine nucleotide energy charge level, where the cell is able to signal pain, or where individual muscle fibers start cramping (fail to relax from contraction in sync with the rest of the muscle), or the whole muscle fails to contract (when walking quickly downhill), allowing the person to appropriately modulate the exertion. Most of the AMP probably spills into blood unchanged, and is gradually returned to the muscle cell, if its concentration there falls due to gradual recharge to ATP. The blood thus plays a role of a big AMP buffer. Idle muscles may also take up some free AMP. The spillover also limits, how much the residual AMPD activity can be amplified in this state. Thus, it may take the residual AMPD activity less time to build up citric acid cycle intermediates, when the whole body is warmed up for an exercise at the same time, rather than a specific group of muscles needed in the exercise. In case of leg muscles, where circulation is substantially dependent on their cyclical contraction when the body is upright, a small but useful degree of initial up-regulation of the citric acid cycle may be achieved just by standing still for a few minutes. It is most useful when a long period of rest, or sitting in a vehicle, must be followed by brisk walking. If the person keeps standing still for longer, rather than restoring circulation in the leg muscles (e.g.

==== Eliminated in primary ==== Hector Cabildo, entrepreneur Raul Castaneda, retiree Marisela Chavez, retiree Deliris Montanez Berrios, retired medical worker and Democratic candidate for this district in 2022 Ruben Rios, teacher

Sources: en.wikipedia.org

Supporting material

In two weeks' fighting, Hoepner's forces advanced 60 km (37 mi) (4 km (2.5 mi) per day). Lacking strength and mobility to conduct battles of encirclement, the Group undertook frontal assaults which proved increasingly costly. A lack of tanks, insufficient motor transport and a precarious supply situation, along with tenacious Red Army resistance and the air superiority achieved by Soviet fighters hampered the attack. The 3rd Panzer Group further north saw slightly better progress, averaging 6 km (3.7 mi) a day. The attack by the 2nd Panzer Group on Tula and Kashira, 125 km (78 mi) south of Moscow, achieved only fleeting and precarious success, while Guderian vacillated between despair and optimism, depending on the situation at the front. Facing pressure from the German High Command, Kluge finally committed his weaker south flank to the attack on 1 December. In the aftermath of the battle, Hoepner and Guderian blamed slow commitment of the south flank of the 4th Army to the attack for the German failure to reach Moscow, grossly overestimating the capabilities of Kluge's remaining forces, according to Stahel. It also failed to appreciate the reality that Moscow was a fortified position which the Wehrmacht lacked the strength to either encircle nor take in a frontal assault, again according to Stahel. In contrast Forczyk lays the blame in part on Kluge's disingenuous lack of commitment to the Moscow operation. As late as 2 December, Hoepner urged his troops forward stating that "the goal [the encirclement of Moscow] can still be achieved".

N2 + 16 MgATP + 8 e− → 2 NH3 + 16 MgADP +16 Pi + H2 where Pi stands for inorganic phosphate. The precise structure of the active site has been difficult to determine. It appears to contain a MoFe7S8 cluster that is able to bind the dinitrogen molecule and, presumably, enable the reduction process to begin. Some species of bacteria and archaea have also been shown to have Vanadium nitrogenases, which contain a VFe3S4 cluster and allows for an alternative pathway of nitrogen fixation in Molybdenum-deficient conditions. The electrons are transported by the associated "P" cluster, which contains two cubical Fe4S4 clusters joined by sulfur bridges.

=== Type II === A civilization capable of harnessing the energy radiated by its own large star – for example, by successfully completing a Dyson sphere or Matrioshka brain – with an energy consumption of ≈4×1033 erg/s. Lemarchand defined such civilizations as being able to harness and channel the entire radiation output of their star. The energy consumption would then be comparable to the luminosity of the Sun, ≈4×1033 erg/s" (≈4×1026 watts).

Sources: en.wikipedia.org

Notes from published material

=== „Kurzmitteilung“ (2014) === Kurzmitteilung [Text Message] is Kermani's first text that he classified as a novel. It is dedicated to the Cologne actress Claudia Fenner, who died of a stroke in July 2005 at the age of 40. In the novel, Maike Anfang, who worked for Ford, dies on the same date and just as unexpectedly. She was supposed to organize an event together with the first-person narrator Dariusch, a freelance event manager. The initiating event of the novel is the text message that gives the book its title, in which Dariusch learns of the sudden death of Maike Anfang, whom he met only fleetingly, while on vacation. The novel narrates the first few days after Maike Anfang’s death, with the question of how to communicate appropriately about death serving as a leitmotif. The protagonist, Dariusch, is less affected by the personal loss than by the sudden confrontation with his own mortality. Although he is able to speak to the relatives of the deceased in an educated and empathetic manner, he is presented as a caricature of a dim-witted, sex-obsessed macho who ends up going on and on about his experience of an awakening in a self-discovery center in the United States.

== Further reading == Payne M.G., Hurst G.S. (1985) Theory of Resonance Ionization Spectroscopy. In: Martellucci S., Chester A.N. (eds) Analytical Laser Spectroscopy. NATO ASI Series (Series B: Physics), vol 119. Springer, Boston, MA. Parks J.E., Young J.P. (2000) Resonance Ionization Spectroscopy 2000: Laser Ionization and Applications Incorporating RIS; 10th International Symposium, Knoxville, Tennessee (AIP Conference Proceedings).

=== First half of 20th century === In the 20th century, many cities built or reorganized formal wholesale market systems for food distribution. For example, Osaka's municipal government documents that its Central Wholesale Market opened in November 1931, following licensing and consolidation steps earlier in the century, and that the wholesale system resumed after wartime disruption. At the same time, the role of wholesale markets changed in many countries as retail formats evolved. FAO notes that the characteristics of wholesale markets have changed "considerably over the last century," in part due to urban growth and the rising role of supermarkets, which changed how food distribution needed to work.

The Israel Defense Forces "battle ration" (Manat Krav) is designed to be shared by four soldiers. It contains 1 can of rice filled vine leaves, 8 small cans of tuna, canned olives, a can of sweet corn, a can of pickled cucumbers, 1 can of halva spread and 1 chocolate spread, a can of peanuts, fruit flavored drink powder, and bread or matzoh crackers. There is also an "ambush pack" of candy and high-energy protein bars. In 2008, Israel introduced a new field ration to supplement the traditional Manat Krav. Unlike previous rations, the new Battle Ration consists of individual, self-heating, ready-to-eat meals packed inside plastic-aluminum trays. They are designed to be carried and used by infantry troops for up to 24 hours, until regular supply lines can be established. Ten menus are available, including chicken, turkey and kebab; each meal pack is supplemented with dry salami, dried fruit, tuna, halva, sweet roll, and preserved dinner rolls. However, as of 2012, the older rations were still in use. In 2011, as a result of the manufacturer going bankrupt, the IDF phased out the can of corned beef (known as 'Loof'), which had been part of the battle ration since the nation's founding. It would be replaced by "ground meat with tomato sauce". Many different recipes and different ways of serving the rations have developed in Israel. With the can of tuna, for example, traditionally cooked using toilet paper soaked in oil.

Sources: en.wikipedia.org

Frequently asked questions

How does the reactive group attach to albumin?

A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.

Does the modification change how the peptide signals?

The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.

Are human half-life figures well established?

Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

Network